RMC No. 59-2022: VAT-Exempt Medicines for Cancer and COVID-19 Treatment Under the CREATE Act

RMC No. 59-2022 updates the VAT-exempt medicine list under CREATE to include certain cancer and COVID-19 treatment medicines. Businesses selling, purchasing, prescribing, distributing, or accounting for qualified medicines for cancer and COVID-19 treatment must check whether their products are covered by the updated List of VAT-Exempt Medicines under Republic Act No. 11534, or the CREATE […]

RMC No. 51-2022: Updated VAT-Exempt Medicines for COVID-19, Hypertension, and Cancer Under the CREATE Act

RMC No. 51-2022 updates the CREATE Act VAT-exempt medicine list for COVID-19, hypertension, and a corrected cancer medicine entry. Businesses dealing in covered medicines should immediately check whether their invoicing, VAT treatment, product master files, and pharmacy or distribution records reflect the latest VAT-exempt medicine list recognized for CREATE Act purposes. RMC No. 51-2022 confirms […]

RMC No. 47-2022: VAT-Exempt COVID-19 Medicines Under the CREATE Act and FDA-Endorsed Updates for Philippine Taxpayers

RMC No. 47-2022 publishes FDA-endorsed updates adding certain COVID-19 treatment medicines to the CREATE Act VAT-exempt medicines list. Businesses selling, purchasing, prescribing, distributing, or accounting for COVID-19 treatment medicines must check whether the medicine is covered by the FDA-endorsed updates to the list of VAT-exempt medicines under the CREATE Act, because covered medicines should be […]

RMC No. 101-2020: Addendum to VAT-Exempt Drugs for Hypertension, Diabetes and High Cholesterol

RMC No. 101-2020 publishes the FDA addendum to VAT-exempt drugs for hypertension, diabetes, and high cholesterol under RA 11467. Businesses selling, purchasing, prescribing, distributing, or accounting for medicines for hypertension, diabetes, and high cholesterol must immediately check whether their drug databases, point-of-sale systems, invoices, tax coding, and VAT treatment reflect the expanded list of VAT-exempt […]

RMC No. 62-2020: VAT-Exempt Prescription Drugs for Diabetes, High Cholesterol and Hypertension Starting January 27, 2020

RMC No. 62-2020 lists VAT-exempt prescription drugs for diabetes, high cholesterol, and hypertension effective January 27, 2020. Pharmacies, hospitals, clinics, importers, distributors, and VAT-registered sellers must treat only the listed prescription drugs and medicines for diabetes, high cholesterol, and hypertension as VAT-exempt beginning January 27, 2020. The key business consequence of RMC No. 62-2020 is […]

RMC No. 4-2019: VAT Exemption for FDA-Listed Diabetes, High-Cholesterol, and Hypertension Drugs

RMC No. 4-2019 publishes the FDA list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs for pharmacy and healthcare VAT compliance. Pharmacies, hospitals, drug distributors, and VAT-registered sellers of medicine must treat the FDA-identified drugs for diabetes, high cholesterol, and hypertension as VAT-exempt once covered by the published FDA list. RMC No. 4-2019 matters because the […]

RMC No. 2-2019: VAT Exemption on Diabetes, High-Cholesterol and Hypertension Drugs in the Philippines

RMC No. 2-2019 implements VAT exemption for FDA-listed diabetes, high-cholesterol, and hypertension drugs, with EDPMS and price reporting rules. Drug manufacturers, distributors, wholesalers, retailers, hospital pharmacies, and other FDA-licensed establishments must apply VAT exemption only to qualified diabetes, high-cholesterol, and hypertension medicines in final form, and only when those medicines are included in the FDA-published […]

RR No. 3-99: Hospitals and Clinics Must Remit 10% Withholding Tax on Medical Practitioners’ Professional Fees

RR No. 3-99 makes hospitals and clinics responsible for remitting 10% expanded withholding tax on doctors’ professional fees and quarterly practitioner reporting. Hospitals and clinics must now take direct responsibility for remitting the 10% expanded withholding tax on professional fees of medical practitioners, including fees paid through the hospital or clinic and fees paid directly […]